Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03037385
Other study ID # BO42863
Secondary ID 2016-004390-41BL
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 17, 2017
Est. completion date March 21, 2024

Study information

Verified date April 2024
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.


Description:

The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll participants with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, or the participants must be intolerant to or the Investigator has determined that treatment with standard therapy is not appropriate, or there must be no accepted standard therapy for their disease.


Recruitment information / eligibility

Status Completed
Enrollment 589
Est. completion date March 21, 2024
Est. primary completion date March 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Diagnosis during dose escalation (Phase 1) - Pathologically documented, definitively diagnosed non-resectable advanced solid tumor. - All participants treated at doses > 120 mg per day must have MTC, or a RET-altered solid tumor per local assessment of tumor tissue and/or blood. - Diagnosis during dose expansion (Phase 2) - All participants (with the exception of participants with MTC enrolled in Groups 3, 4, and 9) must have an oncogenic RET-rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local or central testing of tumor or circulating tumor nucleic acid in blood; as detailed below. - Group 1 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion previously treated with a platinum-based chemotherapy. - Group 2 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion not previously treated with a platinum-based chemotherapy, including those who have not had any systemic therapy. Prior platinum chemotherapy in the neoadjuvant and adjuvant setting is permitted if the last dose of platinum was 4 months or more before the first dose of study drug. - Group 3 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit and was previously treated with cabozantinib and/or vandetanib. - Group 4 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit and was not previously treated with cabozantinib and/or vandetanib. - Group 5 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion, have previously received standard of care (SOC) appropriate for their tumor type (unless there is no accepted standard therapy for the tumor type or the Investigator has determined that treatment with standard therapy is not appropriate), and must not have been eligible for any of the other groups. - Group 6 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion or mutation that was previously treated with a selective tyrosine kinase inhibitor (TKI) that inhibits RET - Group 7 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET mutation previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups - Group 8 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion that was previously treated with a platinum based chemotherapy (China only). - Group 9 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit, and was not previously treated with systemic therapy (except prior cytotoxic chemotherapy is allowed) for advanced or metastatic disease (China only). - Participants must have non-resectable disease. - Dose expansion (Phase 2): Participants in all groups (except Group 7) must have measurable disease per RECIST v1.1 (or RANO, criteria if appropriate for tumor type). - Participants agrees to provide tumor tissue (archived, if available or a fresh biopsy) for RET status confirmation and is willing to consider an on-treatment tumor biopsy, if considered safe and medically feasible by the treating Investigator. For Phase 2, Group 6, participants are required to undergo a pretreatment biopsy to define baseline RET status in tumor tissue. - Participants has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. Key Exclusion Criteria: - Participant's cancer has a known primary driver alteration other than RET. For example, NSCLC with a targetable mutation in EGFR, ALK, ROS1 or BRAF; colorectal with an oncogenic KRAS, NRAS, or BRAF mutation. - Participants had any of the following within 14 days prior to the first dose of study drug: 1. Platelet count < 75 × 10^9/L. 2. Absolute neutrophil count < 1.0 × 10^9/L. 3. Hemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug. 4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present; > 5 × ULN if hepatic metastases are present. 5. Total bilirubin > 1.5 × ULN; > 3 × ULN with direct bilirubin > 1.5 × ULN in presence of Gilbert's disease. 6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance < 40 mL/min. 7. Total serum phosphorus > 5.5 mg/dL - QT interval corrected using Fridericia's formula (QTcF) > 470 msec or history of prolonged QT syndrome or Torsades de pointes, or familial history of prolonged QT syndrome. - Clinically significant, uncontrolled, cardiovascular disease. - Central nervous system (CNS) metastases or a primary CNS tumor that is associated with progressive neurological symptoms. - Clinically symptomatic interstitial lung disease or interstitial pneumonitis including radiation pneumonitis - Participants in Groups 1-5 and 7 (Phase 2) previously treated with a selective RET inhibitor - Participant had a major surgical procedure within 14 days of the first dose of study drug - Participant had a history of another primary malignancy that had been diagnosed or required therapy within the a year prior to the study - Pregnant or breastfeeding female participants

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Adenocarcinoma, Papillary
  • Bronchial Neoplasms
  • Carcinoma
  • Carcinoma, Bronchogenic
  • Carcinoma, Neuroendocrine
  • Carcinoma, Non-Small-Cell Lung
  • Colonic Diseases
  • Colonic Neoplasms
  • Colorectal Neoplasms
  • Digestive System Disease
  • Digestive System Diseases
  • Digestive System Neoplasm
  • Digestive System Neoplasms
  • Endocrine Gland Neoplasm
  • Endocrine Gland Neoplasms
  • Endocrine System Diseases
  • Gastrointestinal Disease
  • Gastrointestinal Diseases
  • Gastrointestinal Neoplasms
  • Head and Neck Neoplasms
  • Intestinal Disease
  • Intestinal Diseases
  • Intestinal Neoplasms
  • Lung Diseases
  • Lung Neoplasm
  • Lung Neoplasms
  • Medullary Thyroid Cancer
  • Neoplasms
  • Neoplasms by Histologic Type
  • Neoplasms by Site
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms, Glandular and Epithelial
  • Neoplasms, Nerve Tissue
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Neuroendocrine Tumors
  • Respiratory Tract Disease
  • Respiratory Tract Diseases
  • Respiratory Tract Neoplasms
  • RET-altered Colon Cancer
  • RET-altered Non Small Cell Lung Cancer
  • RET-altered Papillary Thyroid Cancer
  • RET-altered Solid Tumors
  • Thoracic Neoplasms
  • Thyroid Cancer, Papillary
  • Thyroid Diseases
  • Thyroid Neoplasm
  • Thyroid Neoplasms

Intervention

Drug:
pralsetinib (BLU-667)
pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants

Locations

Country Name City State
Belgium Antwerp University Hospital Edegem
China Beijing Cancer Hospital Beijing
China The affiliated Cancer Hospital, School of Medicine, UESTC Chengdu
China West China Hospital, Sichuan University Chengdu
China Chongqing Cancer Hospital Chongqing
China Fujian Provincial Cancer Hospital Fuzhou City
China First Affiliated Hospital of Gannan Medical University Ganzhou
China Guangdong General Hospital Guangzhou
China Sun Yet-sen University Cancer Center Guangzhou City
China Zhejiang Provincial People?s Hospital Hangzhou
China Jinan Central Hospital Jinan City
China Gansu Cancer Hospital Lanzhou
China Fudan University Shanghai Cancer Center Shanghai City
China Tianjin Medical University Cancer Institute & Hospital Tianjin
China Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan City
China Zhejiang Cancer Hospital Zhejiang
China Henan Cancer Hospital Zhengzhou
France Institut Bergonie Bordeaux
France Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez Lille
France Centre Léon Bérard Lyon
France Centre Antoine Lacassagne Nice
France Institut Curie Paris
France CHU de Rennes - Hopital de Pontchaillo Rennes
France Hôpital Larrey;Université Paul Sabatier Toulouse
France Gustave Roussy Villejuif
Germany Helios Klinikum Emil von Behring GmbH Berlin
Germany Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung Essen
Germany Thoraxklinik Heidelberg gGmbH Heidelberg
Germany Klinikum der Universität München Muenchen
Germany Pius-Hospital; Klinik fuer Haematologie und Onkologie Oldenburg
Hong Kong The Chinese University of Hong Kong Shatin
Italy Asst Grande Ospedale Metropolitano Niguarda Milano Lombardia
Italy IEO; Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative Milano Lombardia
Italy Ospedale Santa Maria Delle Croci Ravenna Emilia-Romagna
Italy Istituto Nazionale Tumori Regina Elena Roma Lazio
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System; Oncology Seoul
Netherlands Antoni van Leeuwenhoek Ziekenhuis Amsterdam
Netherlands Universitair Medisch Centrum Groningen Groningen
Singapore National Cancer Centre Singapore
Spain Hospital Clinic de Barcelona Barcelona
Spain Vall d?Hebron Institute of Oncology (VHIO), Barcelona Barcelona
Spain Institut Catala d Oncologia Hospitalet Hospitalet de Llobregat Barcelona
Spain Hospital Ramon y Cajal; Servicio de Oncologia Madrid
Spain Hospital Universitario 12 de Octubre; Servicio de Oncologia Madrid
Taiwan National Taiwan University Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei City
United Kingdom Guys and St Thomas NHS Foundation Trust, Guys Hospital London
United Kingdom Sarah Cannon Research Institute London
United Kingdom University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility London
United Kingdom The Christie NHS Foundation Trust Manchester
United States Albany Medical Center Albany New York
United States University of Michigan Ann Arbor Michigan
United States University of Colorado Anschutz Medical Campus Aurora Colorado
United States Texas Oncology-Austin Midtown Austin Texas
United States Massachusetts General Hospital. Boston Massachusetts
United States Maryland Oncology Hematology, P.A. Columbia Maryland
United States Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Mayo Clinic-Jacksonville Jacksonville Florida
United States Sylvester Comprehensive Cancer Center; University of Miami School of Medicine Miami Florida
United States Weill Cornell Medical College-New York Presbyterian Hospital New York New York
United States UC Irvine Medical Center Orange California
United States Stellar - Chance Laboratories Philadelphia Pennsylvania
United States Mayo Clinic Hospital Phoenix Arizona
United States Oregon Health & Science University Portland Oregon
United States Mayo Clinic Rochester Rochester Minnesota
United States Washington University School of Medicine in St. Louis Saint Louis Missouri
United States Seattle Cancer Care Alliance Seattle Washington
United States Georgetown University Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Belgium,  China,  France,  Germany,  Hong Kong,  Italy,  Korea, Republic of,  Netherlands,  Singapore,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary (Phase 1) Determination of Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib Cycle 1 (28 days) of treatment for MTD and at the end of every cycle (28 days) for RP2D for approximately 12 months or earlier if participant terminates from the study
Primary (Phase 1) Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Every cycle (28 days) for approximately 12 months or earlier if participant terminates from the study, and 30 days after the last dose
Primary (Phase 2) Overall Response Rate (ORR) As assessed by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO), as appropriate per tumor type Approximately every 8 weeks or 16 weeks based on the treatment cycle
Primary (Phase 2) Number of Participants with AEs and SAEs Every cycle (28 days) for approximately 24 months or earlier if participant terminates from the study, and 30 days after the last dose
Secondary (Phase 1) ORR As assessed by RECIST v1.1 or RANO, as appropriate per tumor type Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (Up to 12 months) in participants without progressive disease
Secondary (Phase 1) RET Gene Status and Correlation Between RET Gene Status and ORR, CBR, DOR, DCR, PFS and Other Antineoplastic Measures Clinical Benefit Rate (CBR), Duration of Response (DOR), Disease Control Rate (DCR), Progression Free Survival (PFS) Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 12 months)
Secondary (Phase 2) CBR Approximately every 8 weeks or 16 weeks based on the treatment cycle
Secondary (Phase 2) DOR Approximately every 8 weeks or 16 weeks based on the treatment cycle
Secondary (Phase 2) DCR Approximately every 8 weeks or 16 weeks based on the treatment cycle
Secondary (Phase 2) PFS Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 84 months)
Secondary (Phase 2) Overall Survival (OS) Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 84 months)
Secondary (Phase 2) RET Gene Status and Correlation Between RET Gene Status and ORR, CBR, DOR, DCR and Other Antineoplastic Measures RET gene status (i.e. gene fusion partner or primary mutation and, for MTC, whether hereditary or sporadic) On Day 1 of Cycle 1 (each cycle is of 28 days), 2 and 3 and every other cycle thereafter up to Cycle 13
Secondary (Phases 1 and 2) Pharmacokinetic Parameters Including Maximum Plasma Drug Concentration (Cmax) Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4
Secondary (Phases 1 and 2) Pharmacokinetic Parameters Including Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC0-24) Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4
Secondary (Phases 1 and 2) Pharmacokinetic Parameters Including Terminal Elimination Half-life (t1/2) Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4
Secondary (Phase 2) Electrocardiogram (ECG) Assessment Using QT Analysis Will be measured from lead II and will be corrected for heart rate (QTc)n using Fridericia's correction factors Effects of BLU-667 on ECG parameters on Cycle 1 Day 1 and Cycle 1 Day 15
Secondary (Phases 1 and 2) Pharmacodynamic Parameters Including Changes in Blood Calcitonin MTC participants only Approximately every 2 weeks in Cycle 1 and monthly through Cycle 3 and every other month through Cycle 13
Secondary (Phases 1 and 2) Pharmacodynamic Parameters Including Tumor Marker, Carcinoembryonic Antigen (CEA) MTC participants only Approximately every 2 weeks in Cycle 1 and monthly through Cycle 3 and every other month through Cycle 13
Secondary (Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC Target by RECIST v1.1 or RANO Approximately every 8 weeks or 16 weeks based on the treatment cycle
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2